Today Aoxing Pharmaceutical Company Inc (AXN) Stock Reaches 52-Week Low

September 17, 2017 - By Vivian Park

The stock of Aoxing Pharmaceutical Company Inc (NYSEMKT:AXN) hit a new 52-week low and has $0.25 target or 3.00 % below today’s $0.26 share price. The 5 months bearish chart indicates high risk for the $19.66M company. The 1-year low was reported on Sep, 17 by Barchart.com. If the $0.25 price target is reached, the company will be worth $589,800 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 1.14% or $0.003 on September 15, reaching $0.258. About 43,624 shares traded. Aoxing Pharmaceutical Company Inc (NYSEMKT:AXN) has declined 40.41% since September 17, 2016 and is downtrending. It has underperformed by 57.11% the S&P500.

More notable recent Aoxing Pharmaceutical Company Inc (NYSEMKT:AXN) news were published by: Thestreet.com which released: “Aoxing Pharmaceutical (AXN) Stock Spikes After Announcing Full Year Net Income” on October 13, 2015, also Prnewswire.com with their article: “Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer” published on February 01, 2016, Thestreet.com published: “Aoxing Pharmaceutical (AXN) Stock Plummeting to Reverse Yesterday’s Gains” on June 10, 2015. More interesting news about Aoxing Pharmaceutical Company Inc (NYSEMKT:AXN) were released by: Seekingalpha.com and their article: “Figuring Out Aoxing Pharmaceutical’s Future” published on December 29, 2015 as well as Benzinga.com‘s news article titled: “Aoxing Pharmaceutical Starts producing Tilidine Hydrochloride Tablets” with publication date: June 30, 2016.

Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical firm specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The company has market cap of $19.66 million. The Firm holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter and active pharmaceutical ingredient (API) products. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: